MX2022012310A - Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. - Google Patents

Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2022012310A
MX2022012310A MX2022012310A MX2022012310A MX2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A
Authority
MX
Mexico
Prior art keywords
methods
multiple sclerosis
bruton
inhibitor
tyrosine kinase
Prior art date
Application number
MX2022012310A
Other languages
English (en)
Spanish (es)
Inventor
Hideki Garren
Edmond Huatung Teng
Aurelien Viaccoz
BUEDINGEN Hans- Christian VON
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022012310A publication Critical patent/MX2022012310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022012310A 2020-04-03 2021-04-01 Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. MX2022012310A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US202063051767P 2020-07-14 2020-07-14
PCT/US2021/025301 WO2021202825A1 (en) 2020-04-03 2021-04-01 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2022012310A true MX2022012310A (es) 2022-10-27

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012310A MX2022012310A (es) 2020-04-03 2021-04-01 Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.

Country Status (13)

Country Link
US (1) US12605376B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125906A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520469A (cg-RX-API-DMAC7.html)
KR (1) KR20220163986A (cg-RX-API-DMAC7.html)
CN (1) CN115916205A (cg-RX-API-DMAC7.html)
AU (1) AU2021249129B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177390A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002699A1 (cg-RX-API-DMAC7.html)
IL (1) IL296990A (cg-RX-API-DMAC7.html)
MX (1) MX2022012310A (cg-RX-API-DMAC7.html)
TW (1) TWI907406B (cg-RX-API-DMAC7.html)
WO (1) WO2021202825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
WO2024238524A1 (en) * 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
US20210113568A1 (en) * 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
EP3914250A1 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
TWI899163B (zh) 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Also Published As

Publication number Publication date
BR112022019846A2 (pt) 2022-11-22
TW202203925A (zh) 2022-02-01
IL296990A (en) 2022-12-01
AU2021249129B2 (en) 2026-06-04
JP2023520469A (ja) 2023-05-17
CN115916205A (zh) 2023-04-04
US12605376B2 (en) 2026-04-21
KR20220163986A (ko) 2022-12-12
TWI907406B (zh) 2025-12-11
EP4125906A1 (en) 2023-02-08
AU2021249129A1 (en) 2022-10-20
CL2022002699A1 (es) 2023-03-31
WO2021202825A1 (en) 2021-10-07
CA3177390A1 (en) 2021-10-07
US20230149395A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
CL2022002699A1 (es) Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.
ZA202306172B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
CA3168146A1 (en) Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
EP1933833B8 (en) Therapy for the treatment of overactive bladder
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
EP4520398A3 (en) Treatment of prostate cancer
MX2024015988A (es) Inhibidores terapeuticos de la tirosina cinasa para la esclerosis multiple y la miastenia grave
ZA202000028B (en) Use of vibegron to treat overactive bladder
FI3972603T3 (fi) Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää
MX2025008009A (es) Moduladores de la proteolisis de bcl6 y metodos de uso asociados
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
WO2021239928A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
MX2022010513A (es) Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MX2025000582A (es) Inhibidores de tirosina cinasa 2 y usos de estos
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
MX2022007304A (es) Uso de lemborexant para tratamiento del insomnio.